Skip to main content

A bone-loss drug given daily to millions of older adults showed up in an unexpected place. It appeared in brain health data from more than 120,000 people. People taking it were much less likely to get dementia than people getting other treatments for the same bone problem. The drug is not new. It is not experimental. It is not expensive. Scientists are still working to explain how it works.

That finding is part of a fast-changing picture of drugs and dementia risk. Some results are reassuring. Others are sobering. It depends on which drug you look at. Some of the most commonly used drugs in the world show measurable links with dementia risk in large studies of people. Those drugs include cholesterol drugs, blood pressure treatments, and hormone therapy. Other drugs, long seen as safe, are raising concerns that deserve a doctor’s care.

Scientists have looked more and more at drugs people already take. They want to know if a drug given for one problem might also lower the risk of Alzheimer’s and related dementias. The seven drugs in this article all have peer-reviewed research behind their dementia links. Some of that research is strong. Some is early. Talk with your doctor before you change any drug you take. Nothing here is a reason to stop or start a drug on your own.

1. Bone drugs (bisphosphonates): a 24% lower risk vs. other treatments?

Nitrogen-containing bisphosphonates are drugs that slow bone loss. Doctors use them for osteoporosis, a disease that weakens bone, and for bones that break easily. They have become one of the more striking findings in dementia research. Scientists at the University of Hong Kong reviewed electronic medical records from more than 120,000 people aged 60 and older.

People taking these bone drugs had a 16% lower risk of Alzheimer’s and related dementias than patients who were not treated. They had a 24% lower risk than people who received other bone-loss drugs. Common types include alendronate, ibandronate, risedronate, and zoledronate.

The 24% figure comes from a study in Alzheimer’s & Dementia by Sing et al. from HKUMed’s LKS Faculty of Medicine. It reflects a head-to-head comparison with other bone-loss drugs. It is not a comparison against no drug at all. Against no treatment, the drop was 16%. Both figures come from the same set of more than 120,000 patients in Hong Kong. They were followed between 2005 and 2020.

Scientists have a proposed idea of how this might work. They call it a “bone-brain axis.” Ching-Lung Cheung is an associate professor in the Department of Pharmacology and Pharmacy at HKUMed. He said: “Emerging evidence points to a bone-brain axis, suggesting a close link between bone and brain health”. The links with lower dementia risk looked strongest in women. They also looked strongest in patients who had suffered hip fractures.

The findings come from a follow-up study. They do not show that bone drugs directly prevent dementia. The study also covered only a Chinese population. That raises questions about whether the results apply elsewhere. As Cheung noted: “Our findings therefore do not prove that bisphosphonate use reduces dementia risk. This needs confirmation in a clinical trial”. For adults already taking these drugs for bone loss, the findings add a biological reason to take the idea seriously. Before this, the connection was mostly theoretical.

Read More: Scientists Warn Common Medications May Be Linked to Dementia.

2. Statins (cholesterol drugs): promising but complicated?

Statins are drugs used to lower cholesterol in the blood. An analysis combining 36 studies found that statins reduced the risk of getting dementia by about 20%. It also reduced the risk of Alzheimer’s by about 30%, according to Alzheimer’s Research UK.

Those numbers come from follow-up research. The picture gets more complicated when you look at randomized controlled trials. Those trials are the gold standard of medical research. There is good evidence that statins given late in life to people at risk of vessel disease do not prevent a drop in memory and thinking, or dementia. This apparent clash may come down to timing. The follow-up benefit may depend on taking statins earlier in life. That would be before the vessel damage that adds to dementia takes hold. Studies have tested whether taking statins later in life reduces dementia risk or improves memory and thinking. They have found no effect.

For people already given statins for heart protection, this research does not give a clear reason to stop them for brain health. For people wondering whether to start them only to prevent dementia, the research does not yet support that either.

3. Nerve-blocking drugs (anticholinergics): a risk that scales with dose?

Anticholinergics are drugs that block acetylcholine. That is a brain chemical involved in memory and thinking. This group includes some common bladder drugs and older allergy drugs. It also includes certain depression drugs. It includes sleep aids like diphenhydramine. That is the active ingredient in many over-the-counter products, including Benadryl. The category covers a broader range of drugs than most people realize.

A Swedish nationwide case-control study in Alzheimer’s Research & Therapy in October 2025 found a clear pattern. Total use of strong nerve-blocking drugs is linked to a higher risk of dementia. The risk rose as the dose and total use rose. Weak nerve-blocking drugs showed no such effect. The link was strongest for urinary antispasmodics, allergy drugs, and psychiatric drugs.

The highest use levels in that 2025 Swedish study were linked to a 66% higher dementia risk compared with people who had never taken strong nerve-blocking drugs. That figure reflects long total use, not occasional use. A safety review of bladder nerve-blocking drugs found a small higher risk of dementia that could not be ruled out. Those affected had used the drugs for between 4 and 20 years before diagnosis. The risk depends on the dose. It also depends on time. It does not come from a single tablet.

You can explore the research on common drugs linked to dementia risk in more depth. That research also covers separate concerns around benzodiazepines.

4. Blood pressure drugs: lower pressure, clearer thinking?

High blood pressure is one of the most established dementia risk factors you can change. It damages blood vessels throughout the body. That includes the brain’s smallest capillaries. Treating it well appears to carry thinking benefits beyond the heart ones.

A 2025 umbrella review in Nature used the GRADE framework to assess the research. It found moderate certainty of a lower dementia risk linked to blood pressure drugs. The same review found no clear difference between blood pressure drug classes. The gain appeared tied to lowering blood pressure itself. It did not appear tied to any specific drug type.

Earlier research in CNS Drugs in 2015 found that blood pressure drugs may help prevent a drop in memory and thinking, and dementia. That was especially true for calcium channel blockers and renin-angiotensin system blockers. Calcium channel blockers include drugs like amlodipine and nifedipine. They work by relaxing blood vessel walls. Some scientists have proposed that they may also reduce calcium overload in neurons. That process is thought to add to brain damage. The more recent wide review suggests the class distinction may matter less than how well blood pressure is controlled.

For people with high blood pressure who are already on a drug, keeping good control appears to be the most direct brain health lesson.

5. GLP-1 drugs (diabetes and weight-loss drugs): the newest signal?

GLP-1 receptor agonists are a drug class that includes semaglutide (Ozempic, Wegovy), liraglutide, and others. They have drawn wide interest for their gains beyond blood sugar control. Dementia risk reduction is now part of that picture.

In the largest study of its kind, GLP-1 drug use was linked to a 10% lower total risk of getting dementia compared with metformin. Dementia occurred in nearly 2.5% of GLP-1 users. It occurred in nearly 5% of metformin users. Taking this type of drug was linked to a 12% lower risk of getting Alzheimer’s. It was also linked to a 25% lower risk of non-vascular dementias compared with metformin use. That research was in BMJ Open Diabetes Research & Care.

These findings apply to people with type 2 diabetes. Type 2 diabetes is itself a risk factor for dementia. The scientists noted that the tracking period was long enough to observe dementia outcomes. It may not fully capture long-term thinking effects, given how Alzheimer’s progresses. Whether these drugs offer the same help in people without diabetes is still an open question.

6. Hormone replacement therapy (HRT): timing matters?

The link between HRT and dementia has produced conflicting results over decades. A large UK Biobank study may be starting to resolve the contradiction. But there is an important caveat.

Scientists followed 183,450 women past menopause for an average of 13.3 years. HRT use was linked to a 10% lower risk of all-cause dementia and Alzheimer’s. The links differed by APOE genotype, menopause type, and lifetime estrogen use. That research was in Alzheimer’s & Dementia in 2026.

For women who underwent surgical menopause, the drop in dementia risk was much larger. Surgical menopause is an abrupt removal of the ovaries. It is not a natural, gradual transition. HRT in this group was linked to a hazard ratio of 0.74. That translates to roughly a 26% lower relative risk.

When HRT was started also shaped the results. The study found that starting HRT in women aged 46 to 56 was linked to a 10% lower risk of dementia. Starting later, especially after age 65, showed no such help. In some earlier trials, starting later was linked to higher risk. The World Health Organization now provides no specific guidance on HRT and dementia risk. That reflects the uncertainty that remains. The 2026 UK Biobank findings may eventually move that guidance. But trial confirmation is still needed.

7. Proton pump inhibitors (acid-reflux drugs): the risk that didn’t hold up?

Proton pump inhibitors are drugs like omeprazole, lansoprazole, and pantoprazole. Doctors give them for acid reflux and stomach ulcers. Earlier research linked them to dementia risk and caused a lot of concern. That concern now appears to have been overstated.

A 2025 wide review using the GRADE framework found no moderate or high certainty evidence linking PPIs to higher dementia risk. A 2024 review of many studies found that none of six separate reviews looking at PPI use and Alzheimer’s showed a clear link. That was a steady null result across multiple independent analyses.

Earlier German studies that raised alarm about PPIs have since been criticized for weak methods. One problem is confounding by indication. That means people who take acid-reflux drugs may have other health problems that independently raise dementia risk. The current weight of research does not support stopping or avoiding PPIs only out of dementia concern. Using the lowest effective dose for the shortest needed time is still good practice for any long-term drug.

What this means for you?

The World Health Organization says more than 55 million people live with dementia. That number could reach 78 million by 2030 and 139 million by 2050, according to the WHO fact sheet. Even a modest drop in risk across a whole population would matter. The drugs reviewed here sit at every point on the research spectrum. There is a strong, steady signal against long-term nerve-blocking use. There are early but biologically plausible findings on bone drugs. And there is a now-reassuring null result on PPIs.

Three practical conclusions come from the research. First, if you’re on a strong nerve-blocking drug long-term, ask your doctor whether a less nerve-blocking option exists for your condition. The 2025 Swedish nationwide study confirmed that risk rises with dose and total use. The drugs most often implicated are bladder antimuscarinics, sedating allergy drugs, and certain depression drugs. They often have alternatives with a lower nerve-blocking burden. Second, if you have bone loss and need a drug, the choice of which drug to use is now a more useful conversation than it was two years ago. Third, managing heart risk factors with established drugs still has one of the strongest combined research bases for brain health. Those factors include blood pressure, cholesterol, and blood sugar. That holds even where how the drugs work differs.

The research here is developing fast. Some findings that look helpful today may be refined by future randomized trials. Do not stop or start any drug without first speaking with your doctor. The factors that determine which drug is right for any person include genetics, other health problems, and existing drugs. Only your clinician can weigh those properly.

Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.